Prenetics Global Ltd (PRE)

Currency in USD
22.9700
+0.0400(+0.17%)
Closed·
22.97000.0000(0.00%)
·
Advertisement
PRE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
22.215023.6850
52 wk Range
11.365027.2400
Key Statistics
Prev. Close
22.93
Open
22.63
Day's Range
22.215-23.685
52 wk Range
11.365-27.24
Volume
135.98K
Average Volume (3m)
228.35K
1-Year Change
86.5963%
Book Value / Share
5.51
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PRE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
35.8571
Upside
+56.10%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Prenetics Global Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Strong Sell

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 35.8571
(+56.10% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Craig-Hallum
Buy40.00+74.14%-New Coverage17/09/2026
StoneX
Buy40.00+74.14%40.00Maintain08/09/2026
B.Riley
Buy37.00+61.08%-New Coverage27/08/2026
Benchmark
Buy40.00+74.14%30.00Maintain15/07/2026
Benchmark
Buy30.00+30.61%-New Coverage16/06/2026

Prenetics Global Ltd Earnings Call Summary for Q2/2026

  • Prenetics Q2 EPS of -$0.53 beat estimates by 25%, but revenue of $46.5M missed forecasts by 5.4%, sending shares down 1.91% to $19.
  • Gross margin improved to 65% from 62% YoY; July marked first-ever positive adjusted free cash flow at $20.9M revenue, implying $251M annual run rate.
  • Company raised FY guidance to $220M-$230M revenue; Q3 expected at $63M-$64M with H2 adjusted EBITDA loss improving to -$8M to -$12M range.
  • IM8 wellness segment drove growth with $45M revenue, up 33% sequentially; new products IM8 Hydration (Q4) and Premium Gummies (Q1 2025) not in guidance.
  • Management emphasized marketing efficiency gains and science-based positioning, maintaining 95% direct-to-consumer focus with no near-term retail expansion plans.
Last Updated: 18/08/2026, 15:18
Read Full Transcript

Earnings

Latest Release
18/08/2026
EPS / Forecast
-0.53 / -0.71
Revenue / Forecast
46.5M / 49.15M
EPS Revisions
Last 90 days

Compare PRE to Peers and Sector

Metrics to compare
PRE
Peers
Sector
Relationship
P/E Ratio
−6.9x−16.5x−0.4x
PEG Ratio
−0.300.010.00
Price/Book
4.2x3.2x2.6x
Price / LTM Sales
2.5x1.6x3.0x
Upside (Analyst Target)
51.8%20.2%57.0%
Fair Value Upside
Unlock−7.7%8.0%Unlock

Prenetics Global Limited operates as a consumer health sciences company in the United States and Hong Kong. The company focuses on advancing human health and longevity through science-backed products under the IM8 brand. It also operates a consumer genetic testing brand in CircleDNA leveraging sequencing technology to deliver personalized reports across various categories. The company was founded in 2014 and is headquartered in Quarry Bay, Hong Kong.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
7.19K0.04%163.31K
Other Institutional Investors
1.22M7.18%27.62M
Public Companies & Retail Investors
15.71M92.78%356.87M
Total
16.94M100.00%384.65M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Prospect Capital Advisors, LLC1.39%235,8005,355
Jane Street Group, LLC1.33%225,0935,112

People Also Watch

89.37
FLXS
+1.13%
4.610
OABI
-3.76%
23.82
XNCR
-0.25%
75.56
CTBI
+0.36%
57.17
DOO
+3.21%

FAQ

What Is the Prenetics Global (NASDAQ: PRE) Share Price Today?

The Prenetics Global stock price today is 22.9700 USD.

What Stock Exchange Does Prenetics Global (PRE) Trade On?

Prenetics Global is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for Prenetics Global?

The stock symbol (also called a 'ticker') for Prenetics Global is "PRE."

What Is the Current Prenetics Global Market Capitalisation?

As of today, Prenetics Global (NASDAQ: PRE) market cap is 388.3800M USD.

What Is Prenetics Global's (PRE) Earnings Per Share (TTM)?

The Prenetics Global EPS is currently -3.4876 (Trailing Twelve Months).

When Is the Next Prenetics Global Earnings Date?

Prenetics Global's next earnings report will be released on 05/11/2026.

Is PRE a Buy or Sell From a Technical Analyst Perspective?

Based on today's Prenetics Global moving averages and other technical indicators, the daily buy/sell signal for PRE stock is Sell.

How Many Times Has Prenetics Global Stock Split?

Prenetics Global has split 2 times. (See the PRE stock split history page for full effective split date and price information.)

How Many Employees Does Prenetics Global Have?

Prenetics Global has 98 employees, based on their latest Companies House report.

What is the current trading status of Prenetics Global (NASDAQ: PRE)?

As of 25/09/2026, Prenetics Global (PRE) is trading at a share price of 22.9700 USD, with a previous close of 22.9300 USD. The stock has fluctuated within a day range of 22.2150 USD to 23.6850 USD, while its 52-week range spans from 11.3650 USD to 27.2400 USD.

What Is Prenetics Global (PRE) Price Target According to Analysts?

The average 12-month price target for Prenetics Global is 35.8571 USD, with a high estimate of 40 USD and a low estimate of 30 USD. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +56.10% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.